XML 68 R57.htm IDEA: XBRL DOCUMENT v3.22.2
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2021
Jun. 30, 2020
Apr. 30, 2020
Mar. 31, 2020
Jan. 31, 2020
Aug. 30, 2019
Oct. 31, 2018
Apr. 30, 2018
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2020
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                 $ 784,395 $ 272,824 $ 983,469 $ 643,945    
Grant funding liability                 2,712,905   2,712,905     $ 4,559,721
Revenue under collaborative research and development arrangements                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                 36,839 82,923 $ 102,734 122,538    
Advaccine | Collaborative Arrangement, Product                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Upfront payment received $ 3,000,000                          
Additional revenue to be achieved 206,000,000                          
Collaboration agreement, payment earned $ 2,000,000                          
Royalty period                     10 years      
Annual maintenance fee                     $ 1,500,000      
Annual maintenance period                     5 years      
Agreement, number of days written notice before termination                     18 months      
Revenues                         $ 5,000,000  
Advaccine | Collaborative Arrangement, Product | Revenue under collaborative research and development arrangements                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                     $ 0 0    
ApolloBio | Collaborative Arrangement, Product                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Additional revenue to be achieved                     $ 20,000,000      
Royalty period                     10 years      
Agreement, number of days written notice before termination                     90 days      
Period from effective date for termination                     1 year      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Collaborative agreement, funding to be received     $ 6,900,000                      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Accounts receivable                 1,400,000   $ 1,400,000      
Collaborative agreement, funding to be received               $ 56,000,000            
Collaborative agreement, period to receive funding for research and development               5 years            
Funding received for research and development                 3,200,000 2,100,000 5,200,000 4,400,000    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | SARS-CoV-2/COVID-19 Vaccine                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Collaborative agreement, funding to be received         $ 9,000,000                  
Funding received for research and development                 243,000 1,100,000 754,000 3,500,000    
Grant funding liability                 2,400,000   2,400,000      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Collaborative agreement, funding to be received     5,000,000                      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Collaborative agreement, funding to be received     $ 1,300,000                      
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Funding received for research and development       $ 5,000,000         0 0 0 893,000    
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Funding received for research and development           $ 1,100,000 $ 2,200,000   6,000   86,000      
Grant funding liability                 298,000   298,000      
Department of Defence | Collaborative Arrangement, Product                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Contra-research and development expense                 2,900,000 13,400,000 6,100,000 21,200,000    
Accounts receivable                 2,900,000   2,900,000     $ 3,600,000
Deferred revenue                 9,000,000   9,000,000      
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Funding received for research and development   $ 54,500,000                        
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Purchase price, procurement contract   $ 10,700,000                        
Collaborative arrangement , revenue from the procurement contract                 $ 625,000,000 $ 0 $ 625,000,000 $ 0